Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaginal DHEA vs Replens for vaginal symptoms in breast cancer survivors
NCT04493333Phase 2Terminated
- Sponsor
- University of Arkansas
- Start
- Jun 2021
- Primary completion
- Jul 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of dehydroepiandrosterone in vaginal atrophy, sponsored by University of Arkansas. Started Jun 2021; status: terminated.
02
Drugs
dehydroepiandrosterone
03
Conditions
vaginal atrophy
Beyond the preview
Go deeper on NCT04493333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493333.